Mutation frequency of NS5A in patients vertically infected with HCV genotype 1 predicts sustained virological response to peginterferon alfa-2b and ribavirin combination therapy

Journal of Viral Hepatitis

Volumn 16, Issue 12, 2009, Pages 853-859

  Jenke, A C W ^a   Moser, S ^a   Orth, V ^a   Zilbauer, M ^a   Gerner, P ^b   Wirth, S ^a  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

HCV; Mutation; NS5A; Vertical infection

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINO ACID; ASPARTATE AMINOTRANSFERASE; BINDING PROTEIN; NONSTRUCTURAL PROTEIN 5A; PEGINTERFERON ALPHA2B; PROTEIN KINASE R BINDING PROTEIN; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS PROTEIN E2;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINO ACID SEQUENCE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOLOGICAL TOLERANCE; MALE; MUTATION RATE; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN DOMAIN; SCHOOL CHILD; SEQUENCE ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VERTICAL TRANSMISSION; VIRUS GENOME; VIRUS LOAD;

ADOLESCENT; AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; DISEASE TRANSMISSION, INFECTIOUS; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; INTERFERON ALFA-2B; MALE; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; POLYETHYLENE GLYCOLS; POLYMERASE CHAIN REACTION; RIBAVIRIN; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME; VIRAL ENVELOPE PROTEINS; VIRAL NONSTRUCTURAL PROTEINS; YOUNG ADULT;

EID: 70449434606     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2009.01140.x     Document Type: Article

References (31)

1. Wirth S, Pieper-Boustani H, Lang T et al. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology 2005 41 : 1013 1018.
2. Wirth S, Lang T, Gehring S, Gerner P. Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C. Hepatology 2002 36 : 1280 1284.
3. Jara P, Hierro L, del V et al. Efficacy and safety of peginterferon-alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection. Pediatr Infect Dis J 2008 27 : 142 148.
4. Bortolotti F, Iorio R, Resti M et al. An epidemiological survey of hepatitis C virus infection in Italian children in the decade 1990-1999. J Pediatr Gastroenterol Nutr 2001 32 : 562 526.
5. Bortolotti F, Verucchi G, Camma C et al. Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease. Gastroenterology 2008 134 : 1900 1907.
6. Jara P, Resti M, Hierro L et al. Chronic hepatitis C virus infection in childhood: clinical patterns and evolution in 224 white children. Clin Infect Dis 2003 36 : 275 280.
7. Casiraghi MA, De Paschale M, Romano L et al. Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth. Hepatology 2004 39 : 90 96.
8. Dore GJ, Freeman AJ, Law M, Kaldor JM. Is severe liver disease a common outcome for people with chronic hepatitis C? J Gastroenterol Hepatol 2002 17 : 423 430.
9. Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J. Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 2000 31 : 211 218. (Pubitemid 30033709)
10. Hofmann WP, Zeuzem S, Sarrazin C. Hepatitis C virus-related resistance mechanisms to interferon alpha-based antiviral therapy. J Clin Virol 2005 32 : 86 91.
11. Enomoto N, Sakuma I, Asahina Y et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996 334 : 77 81. (Pubitemid 26017933)
12. Tan SL, Gale Jr. MJ, Katze MG. Double-stranded RNA-independent dimerization of interferon-induced protein kinase PKR and inhibition of dimerization by the cellular P58IPK inhibitor. Mol Cell Biol 1998 18 : 2431 2443.
13. Gale Jr. M, Katze MG. Molecular mechanisms of interferon resistance mediated by viral-directed inhibition of PKR, the interferon-induced protein kinase. Pharmacol Ther 1998 78 : 29 46.
14. Podevin P, Sabile A, Gajardo R et al. Expression of hepatitis C virus NS5A natural mutants in a hepatocytic cell line inhibits the antiviral effect of interferon in a PKR-independent manner. Hepatology 2001 33 : 1503 1511.
15. Kurosaki M, Enomoto N, Murakami T et al. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy. Hepatology 1997 25 : 750 753.
16. Nakano I, Fukuda Y, Katano Y, Nakano S, Kumada T, Hayakawa T. Why is the interferon sensitivity-determining region (ISDR) system useful in Japan? J Hepatol 1999 30 : 1014 1022.
17. Berg T, Mas MA, Hohne M, Wiedenmann B, Hopf U, Schreier E. Mutations in the E2-PePHD and NS5A region of hepatitis C virus type 1 and the dynamics of hepatitis C viremia decline during interferon alfa treatment. Hepatology 2000 32 : 1386 1395.
18. Sarrazin C, Berg T, Lee JH et al. Mutations in the protein kinase-binding domain of the NS5A protein in patients infected with hepatitis C virus type 1a are associated with treatment response. J Infect Dis 2000 181 : 432 441. (Pubitemid 30131807)
19. Duverlie G, Khorsi H, Castelain S et al. Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity. J Gen Virol 1998 79 (Pt 6 1373 1381.
20. Squadrito G, Orlando ME, Cacciola I et al. Long-term response to interferon alpha is unrelated to "interferon sensitivity determining region" variability in patients with chronic hepatitis C virus-1b infection. J Hepatol 1999 30 : 1023 1027.
21. Zeuzem S, Lee JH, Roth WK. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa. Hepatology 1997 25 : 740 744.
22. Chung RT, Monto A, Dienstag JL, Kaplan LM. Mutations in the NS5A region do not predict interferon-responsiveness in american patients infected with genotype 1b hepatitis C virus. J Med Virol 1999 58 : 353 358.
23. Murphy MD, Rosen HR, Marousek GI, Chou S. Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection. Dig Dis Sci 2002 47 : 1195 1205.
24. Nousbaum J, Polyak SJ, Ray SC et al. Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy. J Virol 2000 74 : 9028 9038.
25. Inchauspe G, Zebedee S, Lee DH, Sugitani M, Nasoff M, Prince AM. Genomic structure of the human prototype strain H of hepatitis C virus: comparison with American and Japanese isolates. Proc Natl Acad Sci USA 1991 88 : 10292 10296.
26. Liu S, Ansari IH, Das SC, Pattnaik AK. Insertion and deletion analyses identify regions of non-structural protein 5A of Hepatitis C virus that are dispensable for viral genome replication. J Gen Virol 2006 87 : 323 327.
27. Appel N, Pietschmann T, Bartenschlager R. Mutational analysis of hepatitis C virus nonstructural protein 5A: potential role of differential phosphorylation in RNA replication and identification of a genetically flexible domain. J Virol 2005 79 : 3187 3194.
28. Tanji Y, Kaneko T, Satoh S, Shimotohno K. Phosphorylation of hepatitis C virus-encoded nonstructural protein NS5A. J Virol 1995 69 : 3980 3986.
29. Asahina Y, Izumi N, Enomoto N et al. Mutagenic effects of ribavirin and response to interferonribavirin combination therapy in chronic hepatitis C. J Hepatol 2005 43 : 623 629.
30. Layden-Almer JE, Kuiken C, Ribeiro RM et al. Hepatitis C virus genotype 1a NS5A pretreatment sequence variation and viral kinetics in African American and white patients. J Infect Dis 2005 192 : 1078 1087.
31. Dustin LB, Rice CM. Flying under the radar: the immunobiology of hepatitis C. Annu Rev Immunol 2007 25 : 71 99.